
    
      This was a multicenter, open-label, uncontrolled, single-arm, 24-week, extension study to
      assess safety, efficacy, and treatment retention during maintenance treatment.

      Eligible patients had completed 1 of 2 primary efficacy and safety studies of the
      higher-bioavailability BNX sublingual tablet formulation (primary study OX219-006
      [NCT01908842] or OX219-007 [NCT01848054]). The total duration of study treatment was 24
      weeks.
    
  